DEVELOPMENT OF HER-2/NEU (HER2) ICD MEMORY IMMUNITY AFTER VACCINATION

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 尽管实体肿瘤的常规治疗最近取得了进展，但乳腺癌和卵巢癌患者在确定治疗后可能会因为残留的显微镜疾病而复发。根除残留亚临床疾病的一种方法是开发专注于产生肿瘤特异性T细胞免疫的肿瘤疫苗。癌症疫苗研究现在证明，患者在免疫后可以产生肿瘤抗原特异性免疫反应。虽然大多数癌症疫苗研究都集中在主动免疫期间产生可测量的免疫，但很少有研究评估免疫的持久性或免疫记忆的产生。事实上，正是对接种抗原的免疫记忆的发展将是预防复发的肿瘤疫苗成功的关键。因此，我们建议确定以前用HER2细胞内域(ICD)DNA疫苗免疫的患者是否对HER2产生记忆T细胞反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Despite recent advances in the conventional treatment of solid tumors, patients with breast and ovarian cancer may relapse after definitive therapy because of residual microscopic disease. One approach to the eradication of residual sub-clinical disease has been the development of tumor vaccines that focus on generating tumor-specific T cell immunity. Cancer vaccine studies have now demonstrated that patients can develop tumor antigen specific immune responses post-immunization. While most cancer vaccine studies have focused on the generation of measurable immunity during active immunization, few studies have evaluated the persistence of immunity or the generation of immunologic memory. Indeed, it is the development of immunologic memory to the vaccinating antigen that would be the key to the success of a tumor vaccine to protect against relapse. Thus, we propose to determine whether patients previously immunized with a HER2 Intracellular Domain (ICD) DNA vaccine develop a memory T cell response to HER2.